LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

ImmunityBio Inc

Gesloten

SectorGezondheidszorg

2.56 6.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.35

Max

2.6

Belangrijke statistieken

By Trading Economics

Inkomsten

37M

-93M

Verkoop

9.9M

26M

Winstmarge

-350.255

Werknemers

685

EBITDA

4.9M

-60M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+231.95% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

2.2B

Vorige openingsprijs

-3.66

Vorige sluitingsprijs

2.56

Nieuwssentiment

By Acuity

50%

50%

173 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

ImmunityBio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2025, 17:20 UTC

Belangrijke Marktbewegers

ImmunityBio Slides Following FDA Refusal-to-File Letter

5 mei 2025, 11:38 UTC

Belangrijke Marktbewegers

ImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment Application

29 jan 2025, 15:59 UTC

Belangrijke Marktbewegers

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

24 okt 2024, 13:50 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Peer Vergelijking

Prijswijziging

ImmunityBio Inc Prognose

Koersdoel

By TipRanks

231.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD  231.95%

Hoogste 8 USD

Laagste 8 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor ImmunityBio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

2 / 2.63Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

173 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
help-icon Live chat